Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy

Autor:	Pauline Campa, Pierre-Marie Girard, Mathieu F. Chevalier, Martine Alhenc-Gelas, Laurence Weiss, Céline Didier, Elena-Maria Manea, Lambert Assoumou, Saïd Taibi, Jean-Louis Paul, Dominique Costagliola
Rok vydání:	2016
Předmět:	Adult Male 0301 basic medicine medicine.medical_specialty Statin Anti-HIV Agents medicine.drug_class T cell HIV Infections Pilot Projects Inflammation CD8-Positive T-Lymphocytes Lymphocyte Activation Virus Replication Systemic inflammation Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Cytotoxic T cell Pharmacology (medical) Rosuvastatin 030212 general & internal medicine Rosuvastatin Calcium Blood Coagulation business.industry Middle Aged 030104 developmental biology Infectious Diseases medicine.anatomical_structure Drug Therapy Combination Female Hydroxymethylglutaryl-CoA Reductase Inhibitors medicine.symptom business Biomarkers CD8 medicine.drug
Zdroj:	JAIDS Journal of Acquired Immune Deficiency Syndromes. 71:390-398
ISSN:	1525-4135
DOI:	10.1097/qai.0000000000000879
Popis:	OBJECTIVE The aim of the trial was to evaluate in patients under antiretroviral therapy (ART) the effect of rosuvastatin on cellular and soluble markers of immune activation/inflammation, as well as to identify patients who better benefit from statin administration. METHODS IMEA-043-CESAR was a phase II open-label pilot trial that enrolled patients under suppressive ART and CD4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71c3cf58c73be48d579b801d172b0cf3 https://doi.org/10.1097/qai.0000000000000879 Zobrazit plný text záznamu